(Q35371197)

8 August 2017

title

Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review (English)

1 reference

ORCID Public Data File 2021

8 August 2017

1 reference

author name string

Theresa R Harring

1

1 reference

8 August 2017

N Thao N Nguyen

2

1 reference

8 August 2017

John A Goss

3

1 reference

8 August 2017

Christine A O'Mahony

4

1 reference

8 August 2017

publication date

13 October 2011

1 reference

International Journal of Hepatology

8 August 2017

published in

1 reference

8 August 2017

volume

2011

1 reference

8 August 2017

page(s)

154541

1 reference

Creative Commons Attribution 3.0 Unported

8 August 2017

copyright license

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Therapeutic strategies for advanced neuroendocrine carcinomas of jejunum/ileum and pancreatic origin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Everolimus for advanced pancreatic neuroendocrine tumors.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Multimodal management of neuroendocrine liver metastases.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

90Y-edotreotide for metastatic carcinoid refractory to octreotide

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Management of advanced neuroendocrine tumors with hepatic metastasis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

The role of mTOR in the management of solid tumors: an overview

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Hepatic neuroendocrine metastases: chemo- or bland embolization?

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Clinical presentation and management of carcinoid tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Neuroendocrine tumors. Biotherapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

MicroRNA expression and function in cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

MicroRNA signatures in human cancers

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Update on the management of neuroendocrine hepatic metastases

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Future aspects of somatostatin-receptor-mediated therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Liver transplantation for treatment of metastatic neuroendocrine tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Antiproliferative effect of somatostatin and analogs

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Cytoreductive hepatic surgery for neuroendocrine tumors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Carboplatin in the treatment of metastatic carcinoid tumours and paraganglioma: a phase II study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience

27 July 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Long-term survival after surgical management of neuroendocrine hepatic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Hepatic neuroendocrine metastases: does intervention alter outcomes?

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Neuroendocrine liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization).

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Hepatic arterial embolization and chemoembolization in the management of patients with large-volume liver metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Transarterial Chemoembolization of Advanced Liver Metastases of Neuroendocrine Tumors – A Retrospective Single-Center Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Combination therapy of transcatheter arterial chemoembolization and arterial administration of antiangiogenesis on VX2 liver tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Treatment with cisplatin and etoposide in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Molecular mechanisms of metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Sunitinib paves the way for targeted therapies in neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

MicroRNAs in tumorigenesis: a primer

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Efficient in vivo microRNA targeting of liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3195553

Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors – Well-Differentiated Jejunal-Ileal Tumor/Carcinoma

26 September 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.4061%2F2011%2F154541

Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors

21 January 2018

1 reference

12 December 2020

Intrahepatic arterial chemoembolization for hepatocellular carcinoma and metastatic neuroendocrine tumors in the era of liver transplantation

1 reference

12 December 2020

Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report

1 reference

12 December 2020

Somatostatin receptors

1 reference

12 December 2020

Use of somatostatin analog in management of carcinoid syndrome

1 reference

12 December 2020

Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach

1 reference

12 December 2020

[Efficacy of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma: a controlled randomized trial]

1 reference

12 December 2020

Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

1 reference

12 December 2020

Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferon

1 reference

12 December 2020

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

12 December 2020

Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: A 15-year single center prospective study

1 reference

12 December 2020

Does immunosuppression alter the growth of metastatic liver carcinoid after orthotopic liver transplantation?

1 reference

12 December 2020

Neuroendocrine hepatic metastases: does aggressive management improve survival?

1 reference

12 December 2020

Expression of vascular endothelial growth factor in digestive neuroendocrine tumours

1 reference

12 December 2020

Identifiers

DOI

10.4061/2011/154541

1 reference

8 August 2017

1 reference

8 August 2017

1 reference